TYPE 2 DIABETES, NON-ALCOHOLIC FATTY LIVER DISEASE AND OXIDATIVE STRESS. THERAPEUTIC APPROACHES (LITERATURE REVIEW AND OWN DATA)

Authors

  • Kravchun N. O. SI «V. Danilevsky Institute of Endocrine Pathology Problems of NAMS of Ukraine», Kharkiv, Ukraine
  • Dorosh O. G. SI «V. Danilevsky Institute of Endocrine Pathology Problems of NAMS of Ukraine», Kharkiv, Ukraine https://orcid.org/0000-0003-4033-282X

DOI:

https://doi.org/10.21856/j-PEP.2012.4.18

Keywords:

Diabetes mellitus

Abstract

Diabetes mellitus (DM) is a widespread systemic chronic disease in all countries of the world, which is characterized by a violation of all types of metabolism, primarily carbohydrate. Type 2 diabetes mellitus has reached the size of a pandemic, and there is a steady tendency to further increase the number of patients. It is expected that by 2030 it will reach 552 million (in 2011 this figure was 366 million). A significant increase in the incidence of diabetes and among the population of Ukraine is no exception: from 194.8 per 100 thousand population in 2005 to 254.9 - in 2011

References

Kozak, B. M. International Diabetes Federation (IDF) highlights growing global impact of diabetes in 5th edition of the Diabetes Atlas [Text] / B. M. Kozak, M. Y. Tjota, K. L. Close // J. Diabetes — 2012. — Vol. 4. — P. 8–17.

Чернобров, А. Д. Довiдник основних показникiв дiяльностi ендокринологiчної служби України за 2011 рiк [Текст] / А. Д. Чернобров // Ендокринологiя. — 2012. — Т. 17, № 1. — 36 с.

Хворостiнка, В. М. Вплив жирової дистрофiї печiнки в поєднаннi з метаболiчним синдромом на особливостi перебiгу ЦД [Текст] / В. М. Хворостiнка, А. В. Власенко // Междунар. эндокрин. журн. — 2007. — № 5 (11). — С. 65–70.

Михальчук, Л. М. Неалкогольна жирова хвороба печiнки [Текст] / Л. М. Михальчук, А. С. Єфiмов // Междунар. эндокринол. журн. — 2010. — № 2. — С. 1–12.

Managing nonalcoholic fatty liver disease [Text] / I. Grattagliano, P. Portincasa, V. O. Palmieri, G. Palasciano // Can. Fam. Physician. — 2007. — Vol. 53 (5). — P. 857–863.

The emerging problem of nonalcoholic steatohepatitis (NASH) [Text] / P. Portincasa, I. Grattagliano,V. O. Palmieri, G. Palasciano // Rom. J. Gastroenterol. — 2005. — Vol. 14 (1). — P. 43–51.

Sanyal, A. J. American Gastroenterological Association, AGA Technical Review on Nonalcoholic Fatty Liver Disease [Text] / A. J. Sanyal // Gastroenterology. — 2002. — Vol. 123, Suppl. 5. — P. 1705–1726.

Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis [Text] / B. Balas, R. Belfort, S. A. Harrison [et al.] // J. Hepatol. — 2007. — Vol. 47. — P. 565–570.

Review article: epidemiology, pathogenesis and potential treatments of paediatric non-alcoholic fatty liver disease [Text] / N. J. Barshop, C. B. Sirlin, J. B. Schwimmer, J. E. Lavine // Alim. pharmacol. therapeutics. — 2008. — Vol. 28 (1). — P. 13–24.

Lerret, S. M. Pediatric nonalcoholic fatty liver disease [Text] / S. M. Lerret, J. A. Skeleton // Gastroenterol.Nurs. — 2008. — Vol. 31. — P. 115–119.

Nanda, K. Non-alcoholic steatohepatitis in children [Text] / K. Nanda // Pediatr. Transplant. — 2004. — Vol. 8, Suppl. 6. — P. 613–618.

Roberts, E. A. Nonalcoholic Fatty Liver Disease (NAFLD): Approach in the Adolescent Patient [Text] / E. A. Roberts, J. Yap // Curr. Treat. Options. Gastroenterol. — 2006. — Vol. 9, Suppl. 5. — P.423–431.

McCallough, A. J. The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease [Text] / A. J. McCallough // Clin. Liver. Dis. — 2004. — Vol. 8. — P. 521–533.

Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies [Text] / E. Fassio, E. Alvarez, N. Dominguez [et al.] // Hepatology. — 2004. — Vol. 40, № 4. — P. 820–826.

Greenfield, V. Recent advances in nonalcholic fatty liver disease [Text] / V. Greenfield, O. Cheung, A. J. Sanyal // Curr. Opin. Gastroenterol. — 2008. — Vol. 24. — P. 320–327.

Nateglinide is useful for nonalcoholic steatohepatitis (NASH) patients with type 2 diabetes [Text] / Y. Morita, T. Ueno, N. Sasaki [et al.] // Hepatogastroenterology. — 2005. — Vol. 52, № 65. —P. 1338–1343.

Prevalence of esophagogastric varices in patients with non-alcoholic steatohepatitis [Text] / S. Nakamura, H. Konishi, M. Kishino [et al.] // Hepatol. Res. — 2008. — Vol. 38, № 6. — P. 572–579.

Ludwig, J. Non-alcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease [Text] / J. Ludwig, T. R. Viggiano // Mayo Clin. Proc. — 1980. — Vol. 55. — P. 434–8.

Hůlek, P. Steatosis and steatohepatitis in diabetic patient [Text] / P. Hůlek, I. Dresslerová // Vnitr. Lek. — 2011. — Vol. –57 (4). — P. 364–367.

The metabolic syndrome as a predictor of nonalcoholic fatty liver disease [Text] / M. Hamaguchi, T. Kojima, N. Takeda [et al.] // Ann. Intern. Med. — 2005. — Vol. 143. — P. 722–728.

Roden, M. Mechanisms of Disease: hepatic steatosis in type 2 diabetes—pathogenesis and clinical relevance [Text] / M. Roden // Nat. Clin. Pract. Endocrinol. Metabol. — 2006. — Vol. 2. — P. 335–348.

Younossi, Z. M. Review Article: Current Management of Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis [Text] / Z. M. Younossi // Aliment. Pharmacol. Ther. — 2008. — Vol. 28 (1). — P. 2–12.

Day, C. P. Steatohepatitis: A tale of two «hits»? [Text] / C. P. Day, O. F.W. James // Gastroenterology. — 1998. — Vol. 114. — P. 842–45.

Garc, M. C. Non-alcoholic steatohepatitis [Text] / M. C. Garc // Journal of Gastroenterology and Hepatology. — 2001. — Vol. 24. — P. 395–402.

Mitochondrial oxidative injury and energy metabolism alteration in rat fatty liver: effect of the nutritional status [Text] / G. Vendemiale, I. Grattagliano, P. Caraceni [et al.] // Hepatology. — 2001. — Vol. 33. — P. 808–815.

Балаболкин, М. И. Роль гликирования белков, окислительного стресса в патогенезе сосудистых осложнений при сахарном диабете [Текст] / М. И. Балаболкин // Сахарный диабет. — 2002. — № 4. — С. 8–16.

Gaidos, J. K. A decision analysis study of the value of a liver biopsy in nonalcoholic steatohepatitis [Text] / J. K. Gaidos, B. E. Hillner, A. J. Sanyal // Liver. Intern. — 2008. — Vol. 28. — P. 650–658.

Clark, J. M. The epidemiology of nonalcoholic fatty liver disease in adults [Text] / J. M. Clark // J. Clin. Gastroenterol. — 2006. — Vol. 40. — P. 39–43.

Rosiglitazone attenuates liver inflammation in a rat model of nonalcoholic steatohepatitis [Text] / V. Tahan, F. Eren, E. Avsar [et al.] // Dig. Dis. Sci. — 2007. — Vol. 52. — P. 3465–3472.

Bergasa, N. V. Aerobic exercise: a potencial therapeutic intervention for patients with liver disease [Text] / N. V. Bergasa, J. Mehlman, K. Bir // Med. Hypotheses. — 2004. — Vol. 62. — P. 935–941.

Kursher, R. F. // Semin. Gastroenterol. — 2002. — Vol. 13. — P. 123–132.

The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-alcoholic steatohepatitis [Text] / Sabuncu T., Nazligui Y., Karaoglanoglu M. [et al.] // Rom. J. Gastroentarol. — 2003. — Vol. 12. — P. 189–192.

Harrison, S. A. New treatments for nonalcoholic fatty liver disease [Text] / S. A. Harrison // Curr. Gastroenterol. — 2006. — Vol. 8. — P. 21–29.

Orlistat reverses fatty infiltration and improves hepatic fibrosis in obese patients with non-alcoholic steatohepatitis (NASH) [Text] / O. Hussein, M. Grosovski, S. Schlesinger [et al.] // Dig. Dis. Sci. — 2007. — Vol. 52. — P. 2512–2519.

Effect of exercise and dietary modifi cation on serum aminotransferase levels in patients with nonalcoholic steatohepatitis [Text] / B. C. Sreenivasa [et al.] // J. Gastroenterol. Hepatol. — 2006. — Vol. 21. — P. 191–98.

Metformin in the treatment of patients with nonalcoholic steatohepatitis [Text] / A. Uygun, A. Kadayifci, A. T. Isik [et al.] // Aliment. Pharmacol. Ther. — 2004. — Vol. 19. — P. 537–544.

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis [Text] / R. Belfort, S. A. Harrison, K. Brown [et al.] // N. Engl. J. Med. — 2006. — Vol. 355. — P. 2297–2307.

Boelsterli, U. A. Toxicological consequences of altered peroxisome proliferator-activated receptor gamma (PPARgamma) expression in the liver: insights from models of obesity and type 2 diabetes [Text] / U. A. Boelsterli, M. Bedoucha // Biochem. Pharmacol. — 2002. — Vol. 63. — P. 1–10.

Isley, W. L. Hepatotoxicity of thiazolidinediones [Text] / W. L. Isley // Expert. Opin. Drug. Saf. — 2003. — Vol. 2. — P. 581–586.

Scheen, A. J. Hepatotoxicity with thiazolidinediones: is it a class effect? [Text] / A. J. Scheen // Drug. Saf. — 2001. — Vol. 24. — P. 873–888.

Management of fatty liver disease with vitamin E and C compared to ursodeoxycholic acid treatment [Text] / G. Ersoz, F. Gunsar, Z. Karasu [et al.] // Turk. J. Gastroenterol. — 2005. — Vol. 16. — P. 124–128.

The natural history of nonalcoholic fatty liver disease: a clinical histopathological study [Text] / S. A. Harrison, S. Torgerson, P. H. Hayashi [et al.] // Am. J. Gastroenterol. — 2003. — Vol. 98 (9). — P. 2485–2490.

Efficacy and safety of oral betaine glucuronate in non-alcoholic steatohepatitis. A double-blind, randomized, parallel-group, placebo-controlled prospective clinical study [Text] / F. Miglio, L. C. Rovati, A. Santoro [et al.] // Arzneimittelforschung. — 2000. — Vol. 50. — P. 722–727.

Oxidative stress and enzymatic antioxidant status in patients with nonalcoholic steatohepatitis [Text] / M. Koruk, S. Taysi, M. Cemil Savas [et al.] // Ann Clin Lab Sci. — 2004. — Vol. 34. — P. 57–62.

Antioxidant supplements for nonalcoholic fatty liver disease and/or steatohepatitis [Text] / F. Lirussi, L. Azzalini, S. Orando [et al.] // Cochrane Database Syst. Rev. — 2007. — Vol. 24 (1). — P. CD004996.

Deneke, S. M. Thiol-based antioxidants [Text] / S. M. Deneke // Curr. Top. Cell. Regul. — 2000. — Vol. 36. — P. 151–80.

Self, W. T. Synthesis and characterization of selenotrisulfide-derivatives of lipoic acid and lipoamide [Text] / W. T. Self, L. Tsai, T. C. Stadtman // Proc. Natl. Acad. Sci. — 2000. — Vol. 97, № 23. — P. 12481–6.

Arivazhagan, P. Effect of DL — alpha-lipoic acid on tissue nucleic acid contents in aged rats [Text] / P. Arivazhagan, C. Panneerselvam // Pharmacol. Res. — 2000. — Vol. 42 (3). — P. 223–226.

Alpha-Lipoic acid treatment decreases serum lactate and pyruvate concentrations and improves glucose effectiveness in lean and obese patients with type 2 diabetes [Text] / T. Konrad, P. Vicini [et al.] // Diabetes Care. — 1999. — Vol. 22 (2). — P. 280–287.

Alpha-lipoic acid: effect on glucose uptake, sorbitol pathway, and energy metabolism in experimental diabetic neuropathy [Text] / Y. Kishi, J. D. Schmelzer, J. K. Yao [et al.] // Diabetes. — 1999. — Vol. 48 (10). — P. 2045–51.

Буеверов, А. О. Неалкогольная жировая болезнь печени: обоснование патогенетической терапии [Текст] / А. О. Буеверов, П. О. Богомолов // Клин. перспективы гастроэнтерол. — 2009. — № 1. — С. 3–9.

Гундерманн, К. Й. Неалкогольная жировая болезнь печени: от определения к лечению [Текст] / К. Й. Гундерманн // Росс. Мед. Вести. — 2009. — Т. XIV, № 2. — С. 1–7.

Long-term (12 months) treatment with an antioxidantdrug (silymarin) is effective on hyperinsulinemia, exogenous insulin need and malondialdehyde levels in cirrhotic diabetic patients [Text] / M. Velussi, A. M. Cernigoi, A. De Monte [et al.]

// J. Hepatol. — 1997. — Vol. 26 — P. 871–879.

Saller, R. The use of silymarin in the treatment of liver diseases. [Text] / R. Saller, R. Meier, R. Brignoli // Drugs. — 2001. — Vol. 61. — P. 2035–2063.

Crocenzi, F. A. Beneficial effects of silymarin on estrogen-induced cholestasis in the rat: a study in vivo and in isolated hepatocyte couplets [Text] / F. A. Crocenzi, E. J. Sanchez Pozzi // Hepatology. — 2001. — Vol. 34(2). — P. 329–339.

Crocenzi, F. A. Silymarin as a new hepatoprotective agent in experimental cholestasis: new possibilities for an ancient medication [Text] / F. A. Crocenzi, M. G. Roma // Curr. Med. Chem. — 2006. — Vol. 13 (9). — P. 1055–74.

Phosphatidylcholine protects against fibrosis and cirrhosis in baboon [Text] / C. S. Lieber, S. J. Robins, J. Li [et al.] // Gastroenterology. — 1994. — Vol. 106. — P. 152–159.

Ma, X. Polyenylphosphatidylcholine attenuates non–alcoholic hepatic fibrosis and accelerate its regression [Text] / X. Ma, J. Zhao, C. S. Lieber // J. Hepatol. — 1996. — Vol. 24. — P. 604–13.

Multimodal treatement resulting in a rapid improvement of fatty liver disease in obese patients [Text] / A. Watanabe, M. Kobayashi, N. Morishita, H. Nagashima // Curr. Ther. Res. — 1988. — Vol. 43. — P. 239–46.

Shoheiber, O. Estimation of the costsavings resulting from the use of ursodiol for the prevention of gallstones in obese patients undergoing rapid weight reduction [Text] / O. Shoheiber, J. E. Biskupiak, D. B. Nash // Intern. J. Obes. Relat. Metabol. Disord. — 1997. — Vol. 21. — P. 1038–1045.

Randomized placebocontrolled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis [Text] / J. F. Dufour, C. M. Oneta,J. J. Gonvers [et al.] // Clin. Gastroenterol. Hepatol. — 2006. — Vol. 4. — P. 1537–1543.

Ursodeoxycholic acid in the treatment of nonalcoholic steatohepatitis: Results of a prospective clinical controlled trial (Abstract) [Text] / C. Guma, L. Viola, M. Thome [et al.] // Hepatology. — 1997. — Vol. 26. — P. 387A.

Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis [Text] / M. Kiyici, M. Gulten, S. Gurel [et al.] // J. Gastroenterol. — 2003. — Vol. 17. — P. 713–718.

Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial [Text] / K. D. Lindor, K. V. Kowdley, E. J. Heathcote [et al.] // Hepatology. — 2004. — Vol. 39. — P. 770–778.

Буеверов, А. О. Жирная печень: причины и последствия [Текст] / А. О. Буеверов // Практический врач. — 2002. — № 1. — С. 36–38

Ивашкин, В. Т. Болезни органовпищеварения [Текст] / В. Т. Ивашкин, Ю. О. Шульпекова // Рус. мед. журнал. — 2000. — Т. 2, № 2 — С. 41–45.

Минушкин, О. Н. // Патогенетические и клинические предпосылки использования препарата Гастрофект при заболеваниях печени [Текст] / О. Н. Минушкин, Л. В. Масловский, С. И. Леонтьев // Трудный пациент. — 2005. — Т. 3, № 1. — С. 3–7.

Kuntzm, E. Hepatology, Principles and practice: history, morphology, biochemistry, diagnostics, clinic, therapy [Text] / E. Kuntz, H. D. Kuntz // Berlin Heidelberg New York Springer. Verlag. — 2000. — P. 825.

Ghayour-Mobarhan, M. Association between oxidative stress and inflammatory markers in subjects with and without traditional coronary risk factors [Text] / M. Ghayour-Mobarhan // The 2nd Latin America Congress on Controversies to consensus in diabetes, obesity and hypertension: abstr., Rio de Janeiro, Brazil, 22–25 march, 2012. — P. 16A.

Кравчун, Н. О. Клiнiко-антропометрична характеристика хворих на цукровий дiабет 2 типу iз неалкогольною жировою хворобою печiнки [Текст] / Н. О. Кравчун, О. В. Землянiцина, О. Г. Дорош // Пробл. ендокрин. патологiї. —

— № 1. — С. 33–37.

Кравчун, Н. О. Стан лiпiдного метаболiзму та перекисне окислення лiпiдiв у хворих з рiзними виявами метаболiчного синдрому [Текст] / Н. О. Кравчун // Укр. терапевт. журн. — 2006. — № 2. — С. 39–42.

Downloads

Published

2012-12-25

How to Cite

Kravchun N. О., & Dorosh, O. (2012). TYPE 2 DIABETES, NON-ALCOHOLIC FATTY LIVER DISEASE AND OXIDATIVE STRESS. THERAPEUTIC APPROACHES (LITERATURE REVIEW AND OWN DATA). Problems of Endocrine Pathology, 42(4), 116-125. https://doi.org/10.21856/j-PEP.2012.4.18

Most read articles by the same author(s)

Similar Articles

<< < 3 4 5 6 7 8 9 10 11 12 > >> 

You may also start an advanced similarity search for this article.